查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1874007

慢性咳嗽市場

Chronic Cough Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024年，慢性咳嗽市場價值約為91.5億美元，預計到2031年將成長至136億美元。該市場預計在2031年至2032年間將維持8.2%的年複合成長率（CAGR）。人們對呼吸系統疾病的認知不斷提高、醫學研究和治療方案的進步，以及持續的藥物研發趨勢，預計將成為影響慢性咳嗽市場的重要因素。

慢性咳嗽市場分析

全球慢性咳嗽市場主要由慢性肺部感染發病率上升以及新型慢性咳嗽療法的推出所推動，因為持續咳嗽是慢性肺部感染的常見症狀。此外，人們日益重視呼吸系統健康，以及政府和非政府組織的相關舉措，也促進了市場成長。

慢性咳嗽市場概覽

慢性咳嗽是指持續八週或更長的咳嗽。它可能由感染、氣喘和胃食道逆流（GERD）引起。慢性咳嗽的相關症狀包括鼻後滴漏（黏液反流感）、頭痛、頻繁清嗓、咽喉痛、聲音沙啞、呼吸急促、喘息、口中發酸和胃灼熱。近年來，醫療基礎設施、診斷服務和病患教育計畫的投入顯著增加，旨在加強慢性咳嗽的管理和早期發現。

戰略洞察

慢性咳嗽市場促進因素與機遇

慢性咳嗽發生率上升將推動市場成長

感染、肺部疾病和支氣管炎等疾病可能是導致慢性咳嗽的因素。全球氣喘病例的增加，尤其是在兒童和成人中，是一個值得關注的現象。一項題為「慢性咳嗽的盛行率、其危險因子和人群歸因風險：一項多國橫斷面研究」（發表於2024年2月）的研究報告稱，慢性咳嗽的盛行率在2%至18%之間。常見的慢性咳嗽相關因素包括吸菸、氣喘、慢性阻塞性肺病（COPD）、肥胖、上呼吸道咳嗽症候群（UACS）和胃食道逆流（GERD）。

預計老年人口成長將增加對慢性咳嗽治療的需求

老年人更容易患慢性咳嗽，老化是免疫力下降的主要因素。隨著年齡成長，器官和健康組織會退化，引發各種健康問題，慢性咳嗽在老年族群中尤其常見。隨著年齡成長，呼吸系統功能逐漸衰退，增加肺炎、流感等呼吸道感染的風險。

全球人口老化日益加劇，已開發國家和發展中國家的死亡率均下降。醫療保健水準的提高改善了公眾健康，從而延長了預期壽命。世界衛生組織（世衛組織）預測，到2050年，全球60歲及以上人口預計將達到21億，其中80歲及以上人口數量預計將在2020年至2050年間成長兩倍，達到4.26億。因此，不斷成長的老齡人口很可能在預測期內推動對慢性咳嗽治療的需求。

慢性咳嗽市場報告細分分析

慢性咳嗽市場分析按藥物類別、給藥途徑和配銷通路進行細分。

  • 依藥物類別分類，市場包括抗組織胺、皮質類固醇、減充血劑、複方製劑、抗生素、抑酸劑及其他類別。 2023年，複方製劑佔據了最大的市場佔有率。
  • 依給藥途徑分類，市場可分為口服、注射、吸入和其他途徑。 2023年，口服途徑佔最大的市佔率。
  • 就分銷管道而言，市場分為醫院藥房、線上藥房和零售藥房，其中醫院藥房在 2023 年將引領市場。

按地域分類的慢性咳嗽市場佔有率分析

慢性咳嗽市場報告的地理分析分為五個地區：北美、亞太、歐洲、中東和非洲以及南美和中美洲。

北美一直是慢性咳嗽市場的主導地區。預計在預測期內，非處方藥（OTC）需求的成長將是推動該地區收入成長的重要因素。此外，慢性咳嗽病例的增加、老年人口的快速成長、車輛污染的加劇以及人們對先進治療方案的認知不斷提高，都促進了對止咳藥的需求。

慢性咳嗽市場報告範圍

慢性咳嗽市場新聞及最新動態

慢性咳嗽市場評估是基於從一手和二手研究中獲得的定性和定量資料，包括主要企業出版物、協會資料和資料庫。慢性咳嗽市場的最新發展包括：

  • 臨床階段生物製藥公司Trevi Therapeutics, Inc.宣布啟動其在研療法Haduvio（口服納布啡緩釋片）的2b期CORAL臨床試驗，該療法旨在治療特發性肺纖維化（IPF）、難治性慢性咳嗽（RCC）和結節性癢疹引起的慢性咳嗽患者。本試驗將評估三種劑量Haduvio與安慰劑在約160名伴隨慢​​性咳嗽的IPF患者的療效。 （資料來源：Trevi Therapeutics，新聞稿，2023）
  • 加拿大臨床階段藥物研發公司Algernon Pharmaceuticals Inc.宣布，已完成與美國私人藥物研發公司Seyltx Inc.的協議，Seyltx Inc.將收購Algernon的NP-120（伊芬普羅地爾）研發專案。 （資料來源：Algernon Pharmaceuticals Inc.，新聞稿，2024年）

慢性咳嗽市場報告涵蓋範圍及成果

這份題為《慢性咳嗽市場規模及預測（2021-2031）》的報告對市場進行了全面分析，涵蓋以下領域：

  • 涵蓋範圍內所有關鍵細分市場的全球、區域和國家層面的市場規模和預測
  • 市場動態，例如促進因素、限制因素和關鍵機會
  • 未來主要趨勢
  • 詳細的PEST/波特五力模型與SWOT分析
  • 全球及區域市場分析，涵蓋關鍵趨勢、主要參與者、法規及最新發展
  • 產業格局和競爭分析，包括市場集中度、熱力圖分析、主要參與者和最新發展動態
  • 公司詳細概況

目錄

第1章：引言

第2章：慢性咳嗽市場及主要結論

第3章：研究方法

  • 覆蓋範圍
  • 二手研究
  • 初步研究

第4章：慢性咳嗽市場及市場格局

  • 概述
  • PEST分析
    • 北美和 PEST 分析
    • 歐洲和PESTA分析
    • 亞太地區及PEST分析
    • 中東和非洲及PEST分析
    • 南美洲和中美洲
  • 專家意見

第5章：慢性咳嗽市場及主要市場動態

  • 市場促進因素
    • 慢性咳嗽發生率上升
    • 治療慢性咳嗽的產品研發不斷推進
  • 市場限制
    • 產品召回
  • 市場機遇
    • 人口老化預計將推動對慢性咳嗽治療的需求。
  • 未來趨勢
    • 藥物研發的持續趨勢
  • 影響分析

第6章：慢性咳嗽市場及全球分析

  • 全球慢性咳嗽市場收入預測與分析
  • 全球慢性咳嗽市場（依地域分類）－預測與分析
  • 關鍵參與者的市場定位

第7章：慢性咳嗽市場分析及藥物分類

  • 概述
  • 慢性咳嗽藥物市場收入佔有率（按藥物類別分類，2024 年和 2031 年）
  • 抗組織胺藥
  • 皮質類固醇
  • 減充血劑
  • 複方藥物
  • 抗生素
  • 酸阻斷劑
  • 其他藥物類別

第8章：慢性咳嗽市場及給藥途徑

  • 概述
  • 慢性咳嗽藥物市場（按給藥途徑分類），2024 年和 2031 年（%）
  • 口服
  • 注射
  • 吸入
  • 其他給藥途徑

第9章：慢性咳嗽市場及配銷通路

  • 概述
  • 慢性咳嗽市場（按配銷通路分類），2024 年和 2031 年（%）
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章：慢性咳嗽市場及地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 中東和非洲
    • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
  • 南美洲和中美洲
    • 南美洲和中美洲
    • 巴西
    • 阿根廷

第11章：新冠肺炎疫情對全球慢性咳嗽市場的影響

  • 北美洲
  • 歐洲
  • 亞太
  • 世界其他地區

第12章：慢性咳嗽市場及產業概況

  • 概述
  • 2016-2020年慢性咳嗽市場成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第13章：公司簡介

  • Novartis AG
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • GlaxoSmithKline plc.
  • Bayer AG
  • MYLAN N.V.
  • Amneal Pharmaceuticals, Inc.
  • Cipla Inc.
  • Reckitt Benckiser Group plc.
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd

第14章：附錄

簡介目錄
Product Code: TIPRE00011584

In 2024, the chronic cough market was valued at approximately US$ 9.15 billion and is anticipated to grow to US$ 13.60 billion by 2031. The market is projected to experience a compound annual growth rate (CAGR) of 8.2% from 2031 to 2031. Increased awareness of respiratory issues, advancements in medical research and treatment options, along with ongoing drug development trends, are expected to be significant factors influencing the chronic cough market.

Chronic Cough Market Analysis

The global chronic cough market is largely propelled by the rising incidence of chronic lung infections, as a persistent cough is a common symptom, and the introduction of new treatments for chronic cough. The market's growth is also supported by a notable shift towards prioritizing respiratory health and wellness, alongside initiatives from both governmental and non-governmental organizations.

Chronic Cough Market Overview

A chronic cough is defined as one that persists for eight weeks or longer. It can be caused by infections, asthma, and gastroesophageal reflux disease (GERD). Symptoms associated with chronic cough include a sensation of mucus running down the throat (postnasal drip), headaches, frequent throat clearing, sore throat, hoarseness, shortness of breath, wheezing, a sour taste in the mouth, and heartburn. There has been a notable increase in investments in healthcare infrastructure, diagnostic services, and patient education programs aimed at enhancing the management and early detection of chronic cough.

Strategic Insights

Chronic Cough Market Drivers and Opportunities

Increasing Incidence of Chronic Cough to Boost Market Growth

Conditions such as infections, lung diseases, and bronchitis are likely contributors to chronic cough. The global rise in asthma cases, particularly among children and adults, is significant. A study titled "Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study" published in February 2024, reported that the prevalence of chronic cough varies between 2% and 18%. Factors commonly linked to chronic cough include smoking, asthma, chronic obstructive pulmonary disease (COPD), obesity, upper airway cough syndrome (UACS), and gastroesophageal reflux disease (GERD).

Growing Elderly Population Expected to Increase Demand for Chronic Cough Treatments

Older adults are more susceptible to chronic cough, with aging being a primary factor in reduced immunity. Age-related degeneration of organs and healthy tissues can lead to various health issues, with chronic cough being prevalent among the elderly. As individuals age, their respiratory systems deteriorate, increasing the likelihood of respiratory infections such as pneumonia and influenza.

The global aging population is on the rise, with both developed and developing nations experiencing lower mortality rates. Improvements in healthcare have enhanced public health, leading to increased life expectancy. According to the World Health Organization (WHO), by 2050, the global population aged 60 and older is expected to reach 2.1 billion, with the number of individuals aged 80 and above projected to triple from 2020 to 2050, reaching 426 million. Consequently, the growing elderly demographic is likely to drive demand for chronic cough treatments during the forecast period.

Chronic Cough Market Report Segmentation Analysis

The chronic cough market analysis is segmented by drug class, route of administration, and distribution channel.

  • By drug class, the market includes antihistamines, corticosteroids, decongestants, combination drugs, antibiotics, acid blockers, and other classes. The combination drug segment held the largest market share in 2023.
  • In terms of route of administration, the market is categorized into oral, injections, inhalation, and other methods. The oral segment accounted for the largest market share in 2023.
  • Regarding distribution channels, the market is divided into hospital pharmacies, online pharmacies, and retail pharmacies, with the hospital pharmacy segment leading the market in 2023.

Chronic Cough Market Share Analysis by Geography

The geographic analysis of the chronic cough market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has been the leading region in the chronic cough market. The increasing demand for over-the-counter (OTC) products is a significant factor expected to drive revenue growth in this region during the review period. Additionally, the rising number of chronic cough cases, a rapidly growing elderly population, increasing vehicle pollution, and heightened awareness of advanced treatment options are contributing to the demand for cough remedy products.

Chronic Cough Market Report Scope

Chronic Cough Market News and Recent Developments

The chronic cough market evaluation is based on qualitative and quantitative data obtained from primary and secondary research, including key corporate publications, association data, and databases. Recent developments in the chronic cough market include:

  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the initiation of its Phase 2b CORAL clinical trial for its investigational therapy Haduvio (oral nalbuphine ER) aimed at patients with chronic cough due to idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, evaluating three doses against placebo in approximately 160 IPF patients with chronic cough. (Source: Trevi Therapeutics, Press Release, 2023)
  • Algernon Pharmaceuticals Inc., a Canadian clinical-stage pharmaceutical development company, announced the completion of its agreement with Seyltx Inc., a privately owned U.S.-based drug development company, for the acquisition of Algernon's NP-120 (Ifenprodil) research program. (Source: Algernon Pharmaceuticals Inc., Press Release, 2024)

Chronic Cough Market Report Coverage and Deliverables

The report titled "Chronic Cough Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key segments included in the scope
  • Market dynamics such as drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis covering key trends, major players, regulations, and recent developments
  • Industry landscape and competition analysis including market concentration, heat map analysis, prominent players, and recent developments
  • Detailed company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Chronic Cough Market and By Drug Class
    • 1.3.2 Chronic Cough Market and By Route of Administration
    • 1.3.3 Chronic Cough Market and By Distribution Channel
    • 1.3.4 Global Chronic Cough Market and By Geography

2. Chronic Cough Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Chronic Cough Market and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America andPEST Analysis
    • 4.2.2 Europe and PESTAnalysis
    • 4.2.3 Asia PacificandPEST Analysis
    • 4.2.4 Middle East andAfrica and PEST Analysis
    • 4.2.5 South and Central America
  • 4.3 Expert Opinion

5. Chronic Cough Market and Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 RisingIncidences of Chronic Cough
    • 5.1.2 Growing ProductDevelopments to Treat Chronic Cough
  • 5.2 Market Restraints
    • 5.2.1 Product Recalls
  • 5.3 Market Opportunities
    • 5.3.1 Aging Populationis Expected to Drive Demand for Chronic Cough Treatment
  • 5.4 Future Trends
    • 5.4.1 Continuous Trendof Drug Development
  • 5.5 Impact Analysis

6. Chronic Cough Market and Global Analysis

  • 6.1 Global Chronic Cough Market Revenue Forecast And Analysis
  • 6.2 Global Chronic Cough Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Chronic Cough Market Analysis and By Drug Class

  • 7.1 Overview
  • 7.2 Chronic Cough Market Revenue Share, by Drug Class (2024 and 2031)
  • 7.3 Antihistamines
    • 7.3.1 Overview
    • 7.3.2 Antihistamines:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Corticosteroids
    • 7.4.1 Overview
    • 7.4.2 Corticosteroids:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Decongestants
    • 7.5.1 Overview
    • 7.5.2 Decongestants:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Combination Drug
    • 7.6.1 Overview
    • 7.6.2 CombinationDrug: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Antibiotics
    • 7.7.1 Overview
    • 7.7.2 Antibiotics:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.8 Acid Blockers
    • 7.8.1 Overview
    • 7.8.2 Acid Blockers:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.9 Other Drug Class
    • 7.9.1 Overview
    • 7.9.2 Other DrugClass: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)

8. Chronic Cough Market and By Route of Administration

  • 8.1 Overview
  • 8.2 Chronic Cough Market, by Route of Administration, 2024 and 2031 (%)
  • 8.3 Oral
    • 8.3.1 Overview
    • 8.3.2 Oral: ChronicCough Market and Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Injections
    • 8.4.1 Overview
    • 8.4.2 Injections:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Inhalation
    • 8.5.1 Overview
    • 8.5.2 Inhalation:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Other Route of Administration
    • 8.6.1 Overview
    • 8.6.2 Other Route of Administration: Chronic Cough Market and Revenue and Forecast to 2031 (US$Million)

9. Chronic Cough Market and By Distribution Channel

  • 9.1 Overview
  • 9.2 Chronic Cough Market, by Distribution Channel, 2024 and 2031 (%)
  • 9.3 Hospital Pharmacy
    • 9.3.1 Overview
    • 9.3.2 HospitalPharmacy: Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Online Pharmacy
    • 9.4.1 Overview
    • 9.4.2 Online Pharmacy:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Retail Pharmacy
    • 9.5.1 Overview
    • 9.5.2 Retail Pharmacy:Chronic Cough Market and Revenue and Forecast to 2031 (US$ Million)

10. Chronic Cough Market and Geographic Analysis

  • 10.1 North America: Chronic Cough Market
    • 10.1.1 Overview
    • 10.1.2 North America:Chronic Cough Market and Revenue and Forecast to 2031 (USD Million)
    • 10.1.3 North America:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
    • 10.1.4 North America:Chronic Cough Market, by Route of Administration , 2024 and 2031 (USD Million)
    • 10.1.5 North America:Chronic Cough Market, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.1.6 North America:Chronic Cough Market, by Country, 2024 and 2031 (%)
    • 10.1.7 US: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.1 US: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.2 US: Chronic CoughMarket, by Drug Class, 2024 and 2031 (USD Million)
      • 10.1.7.3 US: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.1.7.4 US: Chronic Cough Market,by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.1.8 Canada: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.1 Canada: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.2 Canada: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
      • 10.1.8.3 Canada: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.1.8.4 Canada: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.1.9 Mexico: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.1 Mexico: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.2 Mexico: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
      • 10.1.9.3 Mexico: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.1.9.4 Mexico: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
  • 10.2 Europe: Chronic Cough Market
    • 10.2.1 Overview
    • 10.2.2 Europe: ChronicCough Market - Revenue and Forecast to 2031 (USD Million)
    • 10.2.3 Europe: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
    • 10.2.4 Europe: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
    • 10.2.5 Europe: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.2.6 Europe: ChronicCough Market, by Country, 2018 and 2031 (%)
    • 10.2.7 Germany: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.7.1 Germany: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.7.2 Germany: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
      • 10.2.7.3 Germany: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.2.7.4 Germany: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.2.8 UK: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.1 UK: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.2 UK: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.2.8.3 UK: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.2.9 France: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.1 France: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.2 France: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
      • 10.2.9.3 France: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.2.9.4 France: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.2.10 Spain: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.1 Spain: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.2 Spain: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
      • 10.2.10.3 Spain: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.2.10.4 Spain: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.2.11 Italy: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.1 Italy: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.2 Italy: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
      • 10.2.11.3 Italy: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.2.11.4 Italy: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
  • 10.3 Asia Pacific: Chronic Cough Market
    • 10.3.1 Overview
    • 10.3.2 Asia Pacific:Chronic Cough Market - Revenue and Forecast to 2031 (USD Million)
    • 10.3.3 Asia Pacific:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
    • 10.3.4 Asia Pacific:Chronic Cough Market, by Route of Administration , 2024 and 2031 (USD Million)
    • 10.3.5 Asia Pacific:Chronic Cough Market, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.3.6 Asia Pacific:Chronic Cough Market, by Country, 2024 and 2031 (%)
    • 10.3.7 China: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.1 China: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.2 China: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
      • 10.3.7.3 China: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.3.7.4 China: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.3.8 Japan: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.1 Japan: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.2 Japan: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
      • 10.3.8.3 Japan: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.3.8.4 Japan: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.3.9 India: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.1 India: Chronic CoughMarket and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.2 India: Chronic CoughMarket, by Drug Class , 2024 and 2031 (USD Million)
      • 10.3.9.3 India: Chronic CoughMarket, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.3.9.4 India: Chronic CoughMarket, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.3.10 South Korea: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.10.1 South Korea: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.10.2 South Korea: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
      • 10.3.10.3 South Korea: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.3.10.4 South Korea: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.3.11 Australia: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.11.1 Australia: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.11.2 Australia: ChronicCough Market, by Drug Class , 2024 and 2031 (USD Million)
      • 10.3.11.3 Australia: ChronicCough Market, by Route of Administration , 2024 and 2031 (USD Million)
      • 10.3.11.4 Australia: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
  • 10.4 Middle East and Africa: Chronic Cough Market
    • 10.4.1 Overview
    • 10.4.2 Middle East andAfrica: Chronic Cough Market- Revenue and Forecast to 2031 (USD Million)
    • 10.4.3 Middle East andAfrica: Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
    • 10.4.4 Middle East andAfrica: Chronic Cough Market, by Route of Administration, 2024 and 2031 (USDMillion)
    • 10.4.5 Middle East andAfrica: Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
    • 10.4.6 Middle East andAfrica: Chronic Cough Market, by Country, 2024 and 2031 (%)
    • 10.4.7 Saudi Arabia:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.1 Saudi Arabia:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.2 Saudi Arabia:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
      • 10.4.7.3 Saudi Arabia:Chronic Cough Market, by Route of Administration, 2024 and 2031 (USD Million)
      • 10.4.7.4 Saudi Arabia:Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
    • 10.4.8 UAE: Chronic CoughMarketand Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.1 UAE: Chronic CoughMarketand Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.2 UAE: Chronic CoughMarket, by Drug Class, 2024 and 2031 (USD Million)
      • 10.4.8.3 UAE: Chronic CoughMarket, by Route of Administration, 2024 and 2031 (USD Million)
      • 10.4.8.4 UAE: Chronic Cough,Market, by Distribution Channel, 2024 and 2031 (USD Million)
    • 10.4.9 South Africa:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
      • 10.4.9.1 South Africa:Chronic Cough Marketand Revenue and Forecast to 2031 (USD Million)
      • 10.4.9.2 South Africa:Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
      • 10.4.9.3 South Africa:Chronic Cough Market, by Route of Administration, 2024 and 2031 (USD Million)
      • 10.4.9.4 South Africa:Chronic Cough, Market, by Distribution Channel, 2024 and 2031 (USD Million)
  • 10.5 South and Central America: Chronic Cough Market
    • 10.5.1 Overview
    • 10.5.2 South and CentralAmerica: Chronic Cough Market - Revenue and Forecast to 2031 (US$ Million)
    • 10.5.3 South and CentralAmerica: Chronic Cough Market, by Drug Class, 2024 and 2031 (USD Million)
    • 10.5.4 South and CentralAmerica: Chronic Cough Market, by Route of Administration, 2024 and 2031 (USDMillion)
    • 10.5.5 South and CentralAmerica: Chronic Cough Market, by Distribution Channel, 2024 and 2031 (USD Million)
    • 10.5.6 South and CentralAmerica: Chronic Cough Market, by Country, 2024 and 2031 (%)
    • 10.5.7 Brazil: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.5.7.1 Brazil: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.5.7.2 Brazil: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
      • 10.5.7.3 Brazil: ChronicCough Market, by Route of Administration, 2024 and 2031 (USD Million)
      • 10.5.7.4 Brazil: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)
    • 10.5.8 Argentina: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.5.8.1 Argentina: ChronicCough Market and Revenue and Forecast to 2031 (USD Million)
      • 10.5.8.2 Argentina: ChronicCough Market, by Drug Class, 2024 and 2031 (USD Million)
      • 10.5.8.3 Argentina: ChronicCough Market, by Route of Administration, 2024 and 2031 (USD Million)
      • 10.5.8.4 Argentina: ChronicCough Market, by Distribution Channel , 2024 and 2031 (USD Million)

11. Impact of COVID-19 Pandemic on Global Chronic cough Market

  • 11.1 North America: Impact Assessment of COVID-19 Pandemic
  • 11.2 Europe: Impact Assessment Of COVID-19 Pandemic
  • 11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
  • 11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Chronic Cough Market andIndustry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in The Chronic Cough Market, 2016-2020
  • 12.3 Inorganic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Organic Growth Strategies
    • 12.4.1 Overview

13. COMPANY PROFILES

  • 13.1 Novartis AG
    • 13.1.1 Key Facts
    • 13.1.2 BusinessDescription
    • 13.1.3 Products andServices
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 13.2.1 Key Facts
    • 13.2.2 BusinessDescription
    • 13.2.3 Products andServices
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 GlaxoSmithKline plc.
    • 13.3.1 Key Facts
    • 13.3.2 BusinessDescription
    • 13.3.3 Products andServices
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Bayer AG
    • 13.4.1 Key Facts
    • 13.4.2 BusinessDescription
    • 13.4.3 Products andServices
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 MYLAN N.V.
    • 13.5.1 Key Facts
    • 13.5.2 BusinessDescription
    • 13.5.3 Products andServices
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Amneal Pharmaceuticals, Inc.
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products andServices
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Cipla Inc.
    • 13.7.1 Key Facts
    • 13.7.2 BusinessDescription
    • 13.7.3 Products andServices
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Reckitt Benckiser Group plc.
    • 13.8.1 Key Facts
    • 13.8.2 BusinessDescription
    • 13.8.3 Products andServices
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Sun Pharmaceutical Industries Ltd
    • 13.9.1 Key Facts
    • 13.9.2 BusinessDescription
    • 13.9.3 Products andServices
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Aurobindo Pharma Ltd
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 Glossary of Terms